Friday, December 10, 2010

Advancement In Drug Delivery Technologies Push Cancer Care Delivery Market to $6.8 Billion by 2012

Advancement In Drug Delivery Technologies Push Cancer Care Delivery Market to $6.8 Billion by 2012

Advancement in drug delivery technologies push cancer care delivery market to $6.8 billion by 2012.

(PRWEB) August 2, 2007

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the latest developments in cancer drug development and analyzes the most promising solutions that drug delivery companies are providing.

"Drug Delivery Technology: Revolutionizing Cancer Therapies" finds that pipeline products that will crossover from clinical trials and second generation drug delivery chemotherapy agents will help boost the market. There are presently 650 products in clinical development including chemotherapy agents, anti-hormonals, novel targeted therapies, vaccines and gene-based therapies. The report assesses the options available to deliver anti-cancer compounds both now and in the future.

Cancer remains one of the most widespread diseases worldwide. It was the leading cause of death in the U. S. In 2000, 10 million people were diagnosed with cancer globally, and in 10 years time that figure is set to rise to 15 million. The oncology market, estimated at U. S $33 billion in 2006, is predicted to grow by 12% every year.

Present day cancer therapies like chemotherapy and radiation prolong life spans, but tend to target both tumour cells as well as healthy ones. Cancer therapy would greatly benefit from more efficient drug delivery systems, which avoid systemic toxicity and resistance and improve specificity. In order to meet these challenges, there have been significant developments in drug delivery technologies which are now employing a multidisciplinary approach, including passive and targeted systems.

Drug delivery mechanisms are trying to ensure that anti-cancer chemicals are either bound, encapsulated or shielded in to prevent them from being broken down by enzymes while being transported to the tumour cells. They may also be chemically bound and made inactive before they reach their target cells so that they do not affect surrounding healthy cells.

Authors of the report say that companies are also employing the use of chemical - 'homing in' compounds such as tumour-specific antigens or receptors to specifically target cancer cells in their passive delivery platforms.

In the present cancer care delivery market, oral agents are not key drivers. Authors of the report believe however, that as cancers are identified earlier and there is a move towards chronic treatment, there will be a greater emphasis on the development of oral agents especially in scenarios where pre-surgery and post-surgery treatments become necessary.

The study analyzes the market trend up to 2005, and forecasts market growth based on the technology platforms up to both 2012 and 2020. The success of several revamped products that will hit the market in six years are studied and cases provided to highlight the changes in each technology. The report outlines the alliances that have been made between key pharma and drug delivery companies and also points out where progress has been made in the delivery of new oncology products.

"Drug Delivery Technology: Revolutionizing Cancer Therapies" is available in pdf format from Piribo. For more information, go to: http://www. piribo. com/publications/diseases_conditions/cancer/cancer_drug_delivery_technology. html (http://www. piribo. com/publications/diseases_conditions/cancer/cancer_drug_delivery_technology. html)

Piribo product ID: PAV001

About Piribo
Piribo (http:www. piribo. com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.